- Opinion
- [Reporter’s View] Biotech’s confidence and responsibility
- by Son, Hyung-Min Mar 14, 2024 05:42am
- Several biotechnology companies in South Korea have suffered major setbacks while pursuing first-in-class new technology businesses. GenNBio, a company known for xenotransplantation of pancreatic islets, is currently facing the possibility of being dissolved. Due to management disputes, the departure of key R&D personnel, financial diffic
- Policy
- Poteligeo and Livtencity may likely be reimbursed in April
- by Lee, Tak-Sun Mar 14, 2024 05:42am
- Two rare disease drugs, Poteligeo (mogamulizumab, Kyowa Kirin Korea) and Livtencity (maribavir, Takeda Pharmaceuticals Korea), are likely to be added to the reimbursement list next month after completing pricing negotiations with the National Health Insurance Service. According to industry sources on the 13th, the companies have complet
- Policy
- “Calling for promotion of substitute drug dispensation“
- by Lee, Jeong-Hwan Mar 13, 2024 05:32am
- The Ministry of Health and Welfare (MOHW) announced that they are not officially reviewing specifics of a potential policy to promote the dispensing of substitute drugs. Yet, the MOHW agreed on the need to promote the dispensing of a substitute drug for the drug prescribed in a prescription. Promoting the dispensation of substitute drug
- Company
- Yuhan Corp and BMS will copromote Sotyktu and Zeposia
- by Nho, Byung Chul Mar 13, 2024 05:32am
- Yuhan Corp (CEO: Wook-Je Cho) announced that the company has signed a copromotion agreement with BMS Korea (Country Manager: Hye-Young Lee) for BMS’s plaque psoriasis drug ‘Sotyktu (deucravacitinib)’ and ulcerative colitis drug ‘Zeposia (ozanimod)’ on the 11th. This strategic partnership for joint sales and marketing in Korea marks
- Policy
- Companies with superior CP ratings get reduced fines
- by Lee, Jeong-Hwan Mar 13, 2024 05:32am
- The Korea Fair Trade Commission announced the enforcement of the amendment to the Enforcement Decree of the Fair Trade Act, which grants up to a 20% penalty reduction to companies that receive superior ratings through the operation of a Compliance Program (CP), drawing industry-wide attention. Companies that have been operating for more t
- Policy
- ‘A multifaceted approach to reimburse high-priced drugs'
- by Lee, Jeong-Hwan Mar 13, 2024 05:32am
- It has been pointed out that a financial management plan needs to be established for high-priced drugs listed through the general system, as well as a system to evaluate and manage the performance of high-priced drugs that were granted reimbursement through the risk-sharing agreement (RSA) scheme in order to manage the soundness of the Natio
- Company
- Bosulif prescriptions now available at general hospitals
- by Eo, Yun-Ho Mar 13, 2024 05:32am
- Bosulif (bosutinib), a drug used to treat leukemia, is now available for prescription at general hospitals. According to the industry sources, Pfizer Korea’s Bosulif, a drug used to treat Chronic Myelogenous Leukemia (CML), has passed the drug committee (DC) of general hospitals, including Seoul National University Hospital, Seoul St.
- Opinion
- [Reporter’s View] Need momentum to boost investments
- by Kim, Jin-Gu Mar 12, 2024 05:49am
- Investment in the domestic pharma-bio industry is slowly rising, awakening from its long winter slumber. Although it is still too early to call it a full spring compared to the boom the industry had enjoyed in 2021-2022, however, significant signs of recovery are being shown through various indicators. Such change is usually most often n
- Company
- Quadrivalent meningococcal vaccine MenQuadfi approved
- by Eo, Yun-Ho Mar 12, 2024 05:49am
- The quadrivalent meningococcal vaccine MenQuadfi has landed in Korea. The Ministry of Food and Drug Safety granted marketing authorization for Sanofi's invasive meningococcal disease (serogroups A, C, Y, W) vaccine, MenQuadfi (MenACYW-TT) on the 6th. MenQuadfi is a fully liquid quadrivalent meningococcal vaccine that protects against
- Opinion
- [Reporter’s View] Potential drawbacks of expanding RSAs
- by Lee, Tak-Sun Mar 12, 2024 05:49am
- It has been announced that more drugs will be added to the Risk Sharing Agreements (RSAs) track, which will help to improve patient access and reduce uncertainties. In December, the ‘Improvement of the Drug Pricing System to Ensure Fair-value Compensation for Innovative New Drugs and Healthcare Security’ was announced. Under this syste
